Cancer is the most recurrent chronic disease in the world, with human hepatocellular carcinoma (HCC) being the second leading cause of death among neoplasias. The high frequency of HCC relapse and metastasis warrants the development of new diagnostic and therapeutic procedures. In advanced stages, neoplastic cells can evade immune surveillance and express immunosuppressive proteins and cytokines at tumor sites. Nanocomposites conjugated with immunomodulatory agents can increase the main mechanisms of cellular immunity. In this study, we used nanocarriers to transport oligonucleotide sequences (siRNAs) into cancer cells and leukocytes to modulate the activity of tumor microenvironment cells in vitro. Cell membrane-derived nanoparticles (MNPs) were synthesized with lipids and proteins from the plasma membrane of hepatic tumor cells to deliver a large amount of antigenic material to professional antigen-presenting cells (APCs), following their exposure to HCC and immunosuppressive macrophages. To establish a pro-inflammatory response, pure lipid MNPs were incorporated with monophosphoryl lipid A and siRNA to silence the c-MYC (myelocytomatosis) oncogene. Nanocarriers were tested for the following: (a) NP internalization into cancer and immunocompetent cells; (b) immunomodulatory activity by observing the expression of cell surface markers; and (c) in vitro cytotoxicity. The adsorption of plasma proteins on the MNPs surface and their effects on cellular uptake were also investigated. Our results indicate that the nanostructures are stable in biological suspensions, and can reduce CD47 and PD-L1 expression on cancer cells and simultaneously switch APC activity for an anti-tumor response.
Keywords: hepatocellular carcinoma; immunomodulatory nanoparticles; nanomedicine.
© 2022 Wiley Periodicals LLC.